[Skip to content]

European Parkinson's Disease Association
Search our Site

EPNN Journal Issue 06 - Spring 2006

Next issue
Previous Issue
EPNN Journal issue 06
Click on image to download


  • Sex, drugs and rock and roll

    Susan Calne outlines how drug therapy can be responsible for addictive behaviour in PD patients

  • A full life for the PD nurse in Sweden

    Arja Hoglund describes the work she does at the Karolinska hospital in Stockholm

  • New guide to living with Parkinson’s disease

    A guide for people with Parkinson’s, their families and healthcare professionals has been developed in partnership between the EPDA, H Lundbeck A/S and Teva Pharmaceutical Industries Ltd.

  • Patients and Stem Cells - Patient Conference – Brussels

    On December 15 and 16, 2005, the European Federation of Neurological Associations (EFNA) held an important European conference, conducted as an open and interactive forum where – for the first time – the focus was on what patients thought about stem cell research and therapy.

  • An overview of PD care in the United States

    Peter LeWitt describes how PD is managed in the United States.

  • Quality of life changes in PD: what will PDLIFE tell us?

    Lynn Taurah, Alison Forbes, and K Ray Chaudhuri describe the aims and achievements of the PDLIFE study

  • How occupational therapy helps in Parkinson’s disease

    Jelka Jansa discusses how occupational therapy can help patients with PD improve their daily quality of life

  • How will primary care changes impact on nurses?

    Jane Mills discusses how the British government’s plans to instigate a patient-led NHS will change the roles of healthcare professionals

  • Drug restores normal movement in PD model

    A Swedish study has shown that two weeks of local administration of sNN0031 – a compound under development for PD – normalised movement and restored dopamine balance in a rat model.

  • More PD genes identified

    Scientists working in Britain and Belgium have identified 570 genes that behave abnormally during the development of PD.

  • Stem cell therapy
  • Long-term benefits of deep brain stimulation

    A multi-centre study of deep brain stimulation (DBS) of either the subthalamic nucleus (STN) or the globus pallidus (GPi) has shown that the treatment continues to provide significant benefit even after four years of treatment.

  • ADAGIO study enrols across US and Europe

    The ADAGIO study (Attenuation of Disease progression with AGILECT®/ AZILECT® Once-daily), the largest clinical study to investigate disease modification in PD, has now begun enrolling in Europe and North America.

  • Genetically modified cells for PD treatment

    A US study in animals has shown that genetically modified nerve ‘progenitor’ cells can be used as minipumps to deliver nerve growth factor to the brain. Using rats with parkinsonian symptoms, the researchers investigated the effect of human neural progenitor cells engineered to produce glial cell line-derived neurotrophic factor (GDNF).